Cargando…
Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients
SIMPLE SUMMARY: Pancreatic cancer is one of the most deadly cancer types because it usually is not diagnosed until the cancer has spread throughout the body. In this study, we isolate cancer cells found in the blood of pancreatic cancer patients called circulating tumor cells (CTCs) to study their m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773204/ https://www.ncbi.nlm.nih.gov/pubmed/35052825 http://dx.doi.org/10.3390/biomedicines10010146 |
_version_ | 1784636025193103360 |
---|---|
author | Owen, Sarah Prantzalos, Emily Gunchick, Valerie Sahai, Vaibhav Nagrath, Sunitha |
author_facet | Owen, Sarah Prantzalos, Emily Gunchick, Valerie Sahai, Vaibhav Nagrath, Sunitha |
author_sort | Owen, Sarah |
collection | PubMed |
description | SIMPLE SUMMARY: Pancreatic cancer is one of the most deadly cancer types because it usually is not diagnosed until the cancer has spread throughout the body. In this study, we isolate cancer cells found in the blood of pancreatic cancer patients called circulating tumor cells (CTCs) to study their mutation and gene expression profiles. Comparing patients with better and worse survival duration revealed signatures found in these cancer cells. Characterizing these signatures may help improve patient care by using alternative treatment options. ABSTRACT: Pancreatic ductal adenocarcinoma is typically diagnosed at late stages and has one of the lowest five-year survival rates of all malignancies. In this pilot study, we identify signatures related to survival and treatment response found in circulating tumor cells (CTCs). Patients with poor survival had increased mutant KRAS expression and deregulation of connected pathways such as PI3K-AKT and MAPK signaling. Further, in a subset of these patients, expression patterns of gemcitabine resistance mechanisms were observed, even prior to initiating treatment. This work highlights the need for identifying patients with these resistance profiles and designing treatment regimens to circumvent these mechanisms. |
format | Online Article Text |
id | pubmed-8773204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87732042022-01-21 Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients Owen, Sarah Prantzalos, Emily Gunchick, Valerie Sahai, Vaibhav Nagrath, Sunitha Biomedicines Article SIMPLE SUMMARY: Pancreatic cancer is one of the most deadly cancer types because it usually is not diagnosed until the cancer has spread throughout the body. In this study, we isolate cancer cells found in the blood of pancreatic cancer patients called circulating tumor cells (CTCs) to study their mutation and gene expression profiles. Comparing patients with better and worse survival duration revealed signatures found in these cancer cells. Characterizing these signatures may help improve patient care by using alternative treatment options. ABSTRACT: Pancreatic ductal adenocarcinoma is typically diagnosed at late stages and has one of the lowest five-year survival rates of all malignancies. In this pilot study, we identify signatures related to survival and treatment response found in circulating tumor cells (CTCs). Patients with poor survival had increased mutant KRAS expression and deregulation of connected pathways such as PI3K-AKT and MAPK signaling. Further, in a subset of these patients, expression patterns of gemcitabine resistance mechanisms were observed, even prior to initiating treatment. This work highlights the need for identifying patients with these resistance profiles and designing treatment regimens to circumvent these mechanisms. MDPI 2022-01-11 /pmc/articles/PMC8773204/ /pubmed/35052825 http://dx.doi.org/10.3390/biomedicines10010146 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Owen, Sarah Prantzalos, Emily Gunchick, Valerie Sahai, Vaibhav Nagrath, Sunitha Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients |
title | Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients |
title_full | Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients |
title_fullStr | Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients |
title_full_unstemmed | Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients |
title_short | Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients |
title_sort | synergistic analysis of circulating tumor cells reveals prognostic signatures in pilot study of treatment-naïve metastatic pancreatic cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773204/ https://www.ncbi.nlm.nih.gov/pubmed/35052825 http://dx.doi.org/10.3390/biomedicines10010146 |
work_keys_str_mv | AT owensarah synergisticanalysisofcirculatingtumorcellsrevealsprognosticsignaturesinpilotstudyoftreatmentnaivemetastaticpancreaticcancerpatients AT prantzalosemily synergisticanalysisofcirculatingtumorcellsrevealsprognosticsignaturesinpilotstudyoftreatmentnaivemetastaticpancreaticcancerpatients AT gunchickvalerie synergisticanalysisofcirculatingtumorcellsrevealsprognosticsignaturesinpilotstudyoftreatmentnaivemetastaticpancreaticcancerpatients AT sahaivaibhav synergisticanalysisofcirculatingtumorcellsrevealsprognosticsignaturesinpilotstudyoftreatmentnaivemetastaticpancreaticcancerpatients AT nagrathsunitha synergisticanalysisofcirculatingtumorcellsrevealsprognosticsignaturesinpilotstudyoftreatmentnaivemetastaticpancreaticcancerpatients |